Head-to-head · WeighScore
Boston Medical Group vs Renlo Health
By GLP-1 ScorecardUpdated
Score comparison
Renlo Health has the higher recorded score — 79.7/100 to 61.9/100.
Renlo Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. One of the few programs whose headline is the actual monthly rate, with the prescribing physician and the dispensing pharmacy both named.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Boston Medical Group | Renlo Health |
|---|---|---|
| WeighScore | 61.9/100 | 79.7/100 |
| Grade | C | C+ |
| Site position | #315 | #41 |
| Semaglutide | $199/mo (starting strength, rising with dose, compounded) | $199/mo, billed monthly at every dose |
| Tirzepatide | Not disclosed | $269/mo, billed monthly at every dose |
| Coverage | 7 states | Not publicly listed |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Not confirmed |
Site position #315 · C
Strengths
- An established medical group with a defined 12-week program rather than an open-ended subscription
- The price range and the 12-week total are both published, once you reach the costs page
- Semaglutide is prescribed and dispensed under a compounded pathway with clinician oversight
What to consider
- The published rate is a range by dose strength, $199 to $299, so the figure quoted is the floor rather than what a titrated patient pays
- The 12-week program totals $699 including a telemedicine platform fee that is never itemised — about $233/mo all-in, not $199
- The weight-loss landing page carries no price at all; the numbers are two pages deeper, in the FAQ and the costs page
- Semaglutide and tirzepatide are not priced separately — one range covers the whole program
- Compounded semaglutide and tirzepatide are not FDA-approved finished products
Site position #41 · C+
Strengths
- The headline is the real month-to-month rate — no prepay division and no commitment behind an asterisk
- A genuine all-in line: medication, injection supplies, provider evaluation, ongoing care, expedited shipping and unlimited care-team messaging, with no membership or consultation fees
- Names the prescribing physician, Dr. Sean Arora, MD, and the dispensing pharmacy, VialsRX
- Same price at every dose with a price-lock badge
- A four-month money-back guarantee, and cancel anytime with no fee
What to consider
- A struck-through $399 sits beside the price with no published basis — Renlo never says what it was, when it applied or to whom
- That strikethrough comes from a stylesheet rule rather than a struck-out element, so a markup-level check would report the page clean
- A comparison table headed "Most GLP-1 providers" quotes $270, $365 and $445 by dose while naming no provider and citing no source
- A site-wide $50 code means the advertised figure is not the first amount charged
- No lab protocol is published, and there is no oral or brand route
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.